Liposome co-delivery of quercetin and doxorubicin in inhibiting retinoblastoma by regulating epithelial-mesenchymal transition process
Regulating the process of epithelial-mesenchymal transition(EMT)is an essential strategy to inhibit tumor growth and metastasis.This study is based on the EMT process of retinoblastoma and constructs quercetin(QUE)and doxorubicin(DOX)co-loaded liposome(QD Lipo)to investigate the therapeutic effect and mechanisms of combined QUE and DOX treatment on retinoblasto-ma.Single-factor experiments were conducted to optimize the prescription process of QD Lipo.Eventually,spherical particles with a diameter of(108.87±1.93)nm,a PDI of 0.13±0.02,and a Zeta potential of(-34.83±1.92)mV were obtained.The encapsulation rates of QUE and DOX were 96.20％±4.40％and 91.17％±4.41％,respectively.Y79 human retinoblastoma cells were used as an in vitro cellular model,and confocal microscopy demonstrated that QD Lipo could enhance Y79 uptake efficiency.The CCK-8 assay con-firmed that the optimal combination therapy effect of QUE and DOX occurred at a mass ratio of 1∶1 to 1∶2.Flow cytometry showed that QD Lipo enhanced the induction of apoptosis in Y79 cells.Western blot analysis revealed that QD Lipo significantly reduced the ex-pression of EMT pathway-related proteins vimentin and α-SMA.Fluorescence assays detected a significant decrease in ROS levels in Y79 cells after treatment with QD.These results indicated that liposomal co-delivery of QUE and DOX can enhance drug delivery effi-ciency to retinoblastoma cells,inhibit the EMT process in retinoblastoma by downregulating ROS levels,and enhance the cytotoxicity of DOX against retinoblastoma.
NETL
NSTL
万方数据
